Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.

Kokai-Kun JF, Roberts T, Coughlin O, Le C, Whalen H, Stevenson R, Wacher VJ, Sliman J.

Lancet Infect Dis. 2019 May;19(5):487-496. doi: 10.1016/S1473-3099(18)30731-X. Epub 2019 Mar 15.

PMID:
30885591
2.

Characterization of Clostridium difficile isolates collected during a phase 2b clinical study with SYN-004 (ribaxamase) for the prevention of C. difficile infection.

Kokai-Kun JF, Sarver JL, Carman RJ.

Anaerobe. 2018 Oct;53:30-33. doi: 10.1016/j.anaerobe.2018.07.002. Epub 2018 Jul 5. Review.

PMID:
29981838
3.

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.

Kokai-Kun JF, Roberts T, Coughlin O, Sicard E, Rufiange M, Fedorak R, Carter C, Adams MH, Longstreth J, Whalen H, Sliman J.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02197-16. doi: 10.1128/AAC.02197-16. Print 2017 Mar.

4.

Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies.

Roberts T, Kokai-Kun JF, Coughlin O, Lopez BV, Whalen H, Bristol JA, Hubert S, Longstreth J, Lasseter K, Sliman J.

Clin Drug Investig. 2016 Sep;36(9):725-734. doi: 10.1007/s40261-016-0420-0.

PMID:
27283946
5.

Nonclinical Safety Assessment of SYN-004: An Oral β-lactamase for the Protection of the Gut Microbiome From Disruption by Biliary-Excreted, Intravenously Administered Antibiotics.

Kokai-Kun JF, Bristol JA, Setser J, Schlosser M.

Int J Toxicol. 2016 May;35(3):309-16. doi: 10.1177/1091581815623236. Epub 2015 Dec 23.

PMID:
26700136
6.

A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis.

Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, Brozanski BS, Palmer KG, Trautman MS, Escobedo M, Meissner HC, Sasidharan P, Fretz J, Kokai-Kun JF, Kramer WG, Fischer GW, Mond JJ.

Pediatrics. 2011 Aug;128(2):271-9. doi: 10.1542/peds.2010-3081. Epub 2011 Jul 25.

PMID:
21788224
7.

Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice.

Kokai-Kun JF, Chanturiya T, Mond JJ.

J Antimicrob Chemother. 2009 Jul;64(1):94-100. doi: 10.1093/jac/dkp145. Epub 2009 Apr 27.

PMID:
19398455
8.

Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates.

Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, Kokai-Kun JF, Mond JJ, Kramer WG, Fischer GW.

Antimicrob Agents Chemother. 2009 Jul;53(7):2879-86. doi: 10.1128/AAC.01565-08. Epub 2009 Apr 20.

10.

Differential roles of sortase-anchored surface proteins and wall teichoic acid in Staphylococcus aureus nasal colonization.

Weidenmaier C, Kokai-Kun JF, Kulauzovic E, Kohler T, Thumm G, Stoll H, Götz F, Peschel A.

Int J Med Microbiol. 2008 Jul;298(5-6):505-13. doi: 10.1016/j.ijmm.2007.11.006. Epub 2008 Jan 24.

PMID:
18221914
11.

The multifunctional role of antibodies in the protective response to bacterial T cell-independent antigens.

Mond JJ, Kokai-Kun JF.

Curr Top Microbiol Immunol. 2008;319:17-40. Review.

PMID:
18080413
12.

The Staphylococcus aureus surface protein IsdA mediates resistance to innate defenses of human skin.

Clarke SR, Mohamed R, Bian L, Routh AF, Kokai-Kun JF, Mond JJ, Tarkowski A, Foster SJ.

Cell Host Microbe. 2007 May 17;1(3):199-212.

13.

Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model.

Kokai-Kun JF, Chanturiya T, Mond JJ.

J Antimicrob Chemother. 2007 Nov;60(5):1051-9. Epub 2007 Sep 10.

PMID:
17848374
14.

Co-infection of the cotton rat (Sigmodon hispidus) with Staphylococcus aureus and influenza A virus results in synergistic disease.

Braun LE, Sutter DE, Eichelberger MC, Pletneva L, Kokai-Kun JF, Blanco JC, Prince GA, Ottolini MG.

Microb Pathog. 2007 Nov-Dec;43(5-6):208-16. Epub 2007 Aug 3.

PMID:
17689046
15.

Characterization of IsaA and SceD, two putative lytic transglycosylases of Staphylococcus aureus.

Stapleton MR, Horsburgh MJ, Hayhurst EJ, Wright L, Jonsson IM, Tarkowski A, Kokai-Kun JF, Mond JJ, Foster SJ.

J Bacteriol. 2007 Oct;189(20):7316-25. Epub 2007 Aug 3.

16.
17.

Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo.

Kusuma C, Jadanova A, Chanturiya T, Kokai-Kun JF.

Antimicrob Agents Chemother. 2007 Feb;51(2):475-82. Epub 2006 Nov 13.

18.
19.

Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage.

Clarke SR, Brummell KJ, Horsburgh MJ, McDowell PW, Mohamad SA, Stapleton MR, Acevedo J, Read RC, Day NP, Peacock SJ, Mond JJ, Kokai-Kun JF, Foster SJ.

J Infect Dis. 2006 Apr 15;193(8):1098-108. Epub 2006 Mar 13.

PMID:
16544250
20.
22.

Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections.

Weidenmaier C, Kokai-Kun JF, Kristian SA, Chanturiya T, Kalbacher H, Gross M, Nicholson G, Neumeister B, Mond JJ, Peschel A.

Nat Med. 2004 Mar;10(3):243-5. Epub 2004 Feb 1.

PMID:
14758355
23.

In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood.

von Eiff C, Kokai-Kun JF, Becker K, Peters G.

Antimicrob Agents Chemother. 2003 Nov;47(11):3613-5.

24.

Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces.

Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF.

Antimicrob Agents Chemother. 2003 Nov;47(11):3407-14.

25.

Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model.

Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ.

Antimicrob Agents Chemother. 2003 May;47(5):1589-97.

27.

Elastase in intestinal mucus enhances the cytotoxicity of Shiga toxin type 2d.

Kokai-Kun JF, Melton-Celsa AR, O'Brien AD.

J Biol Chem. 2000 Feb 4;275(5):3713-21.

28.
29.

Characterization of membrane-associated Clostridium perfringens enterotoxin following pronase treatment.

Wieckowski EU, Kokai-Kun JF, McClane BA.

Infect Immun. 1998 Dec;66(12):5897-905.

30.

Determination of functional regions of Clostridium perfringens enterotoxin through deletion analysis.

Kokai-Kun JF, McClane BA.

Clin Infect Dis. 1997 Sep;25 Suppl 2:S165-7. No abstract available.

PMID:
9310665
31.

Deletion analysis of the Clostridium perfringens enterotoxin.

Kokai-Kun JF, McClane BA.

Infect Immun. 1997 Mar;65(3):1014-22.

33.

Supplemental Content

Loading ...
Support Center